e-learning
resources
ERJ
2002
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium
Vincken W., van Noord J.A., Greefhorst A.P.M., Bantje Th.A., Kesten S., Korducki L., Cornelissen P.J.G.
Source:
Eur Respir J 2002; 19: 209-216
Journal Issue:
February
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Vincken W., van Noord J.A., Greefhorst A.P.M., Bantje Th.A., Kesten S., Korducki L., Cornelissen P.J.G.. Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium. Eur Respir J 2002; 19: 209-216
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
The Relationship Between Functional Status and Fatigue After COVID-19 Infection
Observational cohort study of pulmonary exacerbations in alpha-1 antitrypsin deficiency
Panel discussion on ERS Statement – A core outcome set for clinical trials evaluating the management of COPD exacerbations
Related content which might interest you:
A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease
Source: Eur Respir J 2002; 19: 217-224
Year: 2002
Tiotropium as essential maintenance therapy in COPD
Source: Eur Respir Rev 2006; 15: 51-57
Year: 2006
Modelling the 5-year cost-effectiveness of tiotropium, salmeterol and ipratropium for the treatment of chronic obstructive pulmonary disease (COPD) in Spain
Source: Eur Respir J 2006; 28: Suppl. 50, 683s
Year: 2006
Dual bronchodilation with once-daily QVA149 reduces exacerbations, improves lung function and health status versus glycopyrronium and tiotropium in severe-to-very severe COPD patients: The SPARK study
Source: Annual Congress 2013 –New bronchodilators for COPD management
Year: 2013
One-year cost-effectiveness of tiotropium versus ipratropium to treat chronic obstructive pulmonary disease
Source: Eur Respir J 2004; 23: 241-249
Year: 2004
The effect of tiotropium on exacerbations and airflow in patients with COPD
Source: Eur Respir J 2006; 27: 547-555
Year: 2006
QVA149 improves lung function and reduces exacerbations compared to tiotropium in patients with severe-to-very severe COPD: The SPARK study
Source: Annual Congress 2013 –Asthma and COPD management: novel clinical findings
Year: 2013
Once-daily QVA149 reduces exacerbations and improves health status in comparison with glycopyrronium and tiotropium in patients with severe-to-very severe COPD: The SPARK study
Source: Annual Congress 2013 –Clinical trials of LAMAs, LABAs, MABAs and theophylline for asthma and COPD
Year: 2013
Resistance to resistance
Source: Annual Congress 2007 - Primary care: delivering the goods: "inhaled therapies"
Year: 2007
Pharmacodynamic steady state of tiotropium in patients with chronic obstructive pulmonary disease
Source: Eur Respir J 2002; 19: 639-644
Year: 2002
Dual bronchodilation with once-daily QVA149 improves lung function and reduces exacerbations in patients with COPD: The IGNITE trials
Source: Annual Congress 2013 –New clinical trials of asthma and COPD drugs
Year: 2013
Impacting patient-centred outcomes in COPD: exacerbations and hospitalisations
Source: Eur Respir Rev 2006; 15: 47-51
Year: 2006
Can roflumilast improve clinical outcomes in moderate-to-severe chronic obstructive pulmonary disease? A meta-analysis
Source: International Congress 2016 – COPD diagnosis and management
Year: 2016
Once-daily QVA149 demonstrates superior improvements in patient-reported dyspnea compared to tiotropium in patients with moderate-to-severe COPD: The BLAZE study
Source: Annual Congress 2013 –Asthma and COPD management: novel clinical findings
Year: 2013
Managing chronic obstructive pulmonary disease (COPD) in real life: the role of adding tiotropium bromide in relation to quality of life and costs
Source: Eur Respir J 2005; 26: Suppl. 49, 292s
Year: 2005
Dual bronchodilation with once-daily QVA149 improves dyspnea and health status and reduces symptoms and rescue medication use in patients with COPD: The IGNITE trials
Source: Annual Congress 2013 –New clinical trials of asthma and COPD drugs
Year: 2013
Clinically important deterioration in patients with COPD using umeclidinium/vilanterol, tiotropium or placebo: Pooled data
Source: International Congress 2015 – Safety of and interactions between current treatments for asthma and COPD
Year: 2015
Early discharge for patients with exacerbations of COPD - a real life cohort study
Source: Annual Congress 2005 - COPD - acute exacerbations
Year: 2005
Inhaled maintenance therapy and risk of first or subsequent emergency department visit/hospitalization in patients with COPD
Source: Annual Congress 2006 - COPD therapy
Year: 2006
Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease
Source: Eur Respir J 2003; 21: 74-81
Year: 2003
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept